Thank you, Mr. Chair.
Thanks to all of the representatives from the agency for attending today.
I'd like to start with Dr. Poliquin. It's good to see you again. I know you've spoken previously to this committee on updates. One of the subject areas is around genomics.
Could you update the committee on how genomics has helped us respond to the pandemic in its more recent phases, and maybe you could comment on the modelling exercises you are currently undertaking?